This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis

This study has been completed.
Information provided by:
Greiner, Jack V., OD DO PhD Identifier:
First received: April 2, 2008
Last updated: NA
Last verified: April 2008
History: No changes posted
To compare the clinical efficacy of olopatadine and fluticasone in a 3-week single center, double-masked, randomized, placebo controlled parallel treatment conjunctival allergen challenge (CAC) study in patients with allergic conjunctivitis

Condition Intervention Phase
Conjunctivitis, Allergic Drug: Olopatadine Drug: Fluticasone Drug: Saline Drug: Artificial tears Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis

Resource links provided by NLM:

Further study details as provided by Greiner, Jack V., OD DO PhD:

Primary Outcome Measures:
  • Ocular itching [ Time Frame: Minutes following CAC ]

Secondary Outcome Measures:
  • Ocular redness [ Time Frame: Minutes following CAC ]

Enrollment: 60
Study Start Date: February 2008
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Drug: Olopatadine
Ophthalmic solution
Active Comparator: 2
Drug: Fluticasone
Nasal spray
Placebo Comparator: 3
Placebo nasal spray
Drug: Saline
Nasal spray
Placebo Comparator: 4
Placebo Eyedrops
Drug: Artificial tears
Ophthalmic Solution

Detailed Description:
Study will evaluate the efficacy of nasal anti-allergic therapy compared to ocular anti-allergic therapy in the prevention of ocular allergic symptoms.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • At least 18 years of age & either sex, any race
  • Willing and able to follow all instructions and attend all study visits
  • Positive history of ocular allergies
  • Reproducible positive ocular allergic reaction induced by conjunctival allergen challenge

Exclusion Criteria:

  • Have planned surgery during trial period
  • Female currently pregnant, planning a pregnancy, or lactating
  • Use of disallowed medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00655109

United States, Massachusetts
Ophthalmic Research Associates, Inc
North Andover, Massachusetts, United States, 01845
Sponsors and Collaborators
Greiner, Jack V., OD DO PhD
Principal Investigator: Jack V Greiner, OD, DO, PhD ORA, Inc.
  More Information

Responsible Party: Jack V. Greiner, OD DO PhD, Ophthalmic Research Associates Identifier: NCT00655109     History of Changes
Other Study ID Numbers: 08-003-04
Study First Received: April 2, 2008
Last Updated: April 2, 2008

Keywords provided by Greiner, Jack V., OD DO PhD:
Allergic conjunctivitis
Allergic rhinoconjunctivitis

Additional relevant MeSH terms:
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Immune System Diseases
Olopatadine Hydrochloride
Ophthalmic Solutions
Lubricant Eye Drops
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Pharmaceutical Solutions
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Antirheumatic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents processed this record on August 18, 2017